Diabetes drugs 'block cancers'

Metformin and glitazones may reduce cancer risk in people with type-2 diabetes and could prevent cancer in people without diabetes, research suggests.

Research by Dr Craig Currie of Cardiff University School of Medicine found metformin protects against cancer in people with type-2 diabetes, but insulin may increase cancer risk in a dose-dependent fashion.

He suggested that metformin could have a role in cancer prevention in people without diabetes.

People with type-2 diabetes on high insulin doses may benefit from screening and combination therapy with metformin.

Dr Jeffrey Johnson also presented data on cancer risk in people with type-2 diabetes. His research showed that the relationship between obesity, type-2 diabetes and cancer appears to be associated with insulin resistance and hyperinsulinemia.

He suggested glitazones may improve cancer outcomes.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins


Already registered?

Sign in